Posted on

Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment For First Time

Delic Partnership With Paradigm Healthcare Of Georgia Brings Clinically Relevant Toxicology Testing To Ketamine Treatment For First Time

Psychedelic Treatment Chain Ketamine Infusion Centers Will Leverage State-of-the-Art Toxicology Testing Solution to Ensure Highest Quality Results Across Locations

Vancouver, British Columbia – September 30, 2021 – Delic Holding Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced a first of its kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, United States, with a focus on high complexity, clinical toxicology, to bring state-of-the-art  testing to  Ketamine Infusion Centers LLC (“KIC”). Through the partnership, KIC will have access to ​​Paradigm’s Benchmark UDT™ toxicology solution that uses LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision-making.

The addition of Paradigm’s innovative Benchmark UDT™ test platform gives KIC the ability to:

  • Identify any type of drug that may already be present in a patient’s system to avoid potential conflicts with ketamine infusion and to ensure patient safety before ketamine treatment is started.
  • Detect very high levels of ketamine and norketamine, thereby enabling KIC clinicians to make patient-specific treatment decisions and to ensure proper ketamine levels are maintained throughout infusion treatment.
  • Compare ketamine and norketamine levels with analytical data captured from Clinifusion EMR, including benchmarks when treatment started and ended, at what point patients began getting better, and the number of times the patient visited the clinics for treatments, to provide the best overview of a patient’s treatment journey.

Matt Stang, founder and CEO of DELIC stated, “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing technology and new reporting tools to clinicians who use psychedelics to treat people with serious behavioral health conditions; We are proud to partner with Paradigm. By integrating their state-of-the-art testing capabilities, KIC will be able to provide patients suffering from depression, anxiety, PTSD and other debilitating conditions the most accurate, personalized ketamine treatment protocol in the industry.”

“We believe this partnership with Paradigm will take patient care to the next level,” said Sonny Diaz, co-founder of KIC. “Their powerful toxicology testing gives us the ability to quickly assess a patient’s system ahead of treatment and develop a custom plan for moving them through the protocol. Paired with data from Clinifusion EMR, we can see exactly when they started to get better and can keep people at the right levels to maintain their wellness. KIC will be the only clinic able to aggregate this type of analytical data and validate the results.”

Catherine Veal, President, Paradigm stated, “We are very excited about this partnership with Delic and KIC. Paradigm is committed to providing the best scientific data available to support KIC and Delic in their efforts to combine laboratory science with the developing science of psychedelic treatments in patient care. Our industry-leading toxicology testing will now be available to help people who struggle with different behavioral health conditions, including PTSD, major depression, anxiety, as they undergo ketamine infusion to find their way back to better health and wellness.”

KIC enables Delic to leverage its central hub of psychedelic education, media, and information sources to patients seeking psychedelic therapy. Delic Corp is uniquely positioned to bring digital awareness to its various holdings under the Delic Corp umbrella, and drive online users to brick and mortar holdings, including KIC’s physical psychedelic clinics.

Over the last 3 years, KIC has expanded from Arizona to California, while overseeing 4,000 treatments delivered to date, and generating over USD$1.5MM in revenue. KIC operates under the Delic Corp umbrella, under the direction and guidance of Diaz, Dr. Christopher Ray, Rogelio Monzon, and Ganesh Acharya.

About Paradigm Healthcare

Paradigm is based in the United States and its laboratory is located in St. Simons, Georgia. Paradigm is accredited through the College of American Pathologists (CAP) and CLIA. Paradigm performs high-complexity toxicology testing. Paradigm’s laboratory personnel are very experienced and understand the challenges clinicians face when using laboratory science to support quality patient care. For more information about Paradigm and its Benchmark UDT™ testing platform and support of KIC, contact Ananda Smith, Sales Director at +1 (602) 689-9102 or anandas@paradigm.healthcare. Paradigm is not affiliated with Paradigm Labs of Arizona.

About Ketamine Infusion Centers

Ketamine Infusion Centers (“KIC”) is the leading ketamine infusion treatment clinic chain and one of the most experienced in the country, operating locations in California and Arizona. KIC’s evidence-based practices, peer-reviewed studies, and superior quality products result in the best standard of care for legal psychedelic treatments to combat chronic diseases and pain disorders. Part of the Delic Corp family, the leading psychedelic wellness platform, KIC is committed to expanding greater treatment access for patients and improving patient outcomes.

About DELIC Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed [6] entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.9

Media and Investor Relations Contact

Rich Rodriguez

rich@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction;  anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

 

Posted on

Lamar Odom To Speak At Meet Delic In Las Vegas

Lamar Odom To Speak At Meet Delic In Las Vegas

NBA superstar to speak at Meet Delic in Las Vegas about his embrace of psychedelic treatments and screen the film which chronicles his near-fatal overdose and recovery with psychedelics. He joins world’s leading experts, scientists, and health & wellness advocates to gather for a two-day immersive edutainment experience at AREA15 from November 6 – 7, 2021.

Vancouver, BC, September 28, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on November 7. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers, earning him NBA championships in 2009 and 2010. He joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the goldwinning U.S. men’s basketball team at the 2004 Athens Olympics.

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. Odom’s keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite him with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine and a preview of the film.

“We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo. The full lineup of keynote speakers and panelists can be found here.

The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.                                                                                                       

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

Posted on

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint

Not for dissemination in the United States or to U.S. newswire services

VANCOUVER, BC September 27, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously announced sale to a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“).

Pursuant to the Private Placement, the Company issued ‎9,000,000 units of the Company (the “Units“) at a price of C$0.285 per Unit and 15,561,404 pre-funded ‎units of the Company (the “Pre-Funded Units“) at a price of C$0.2849. Each Unit is comprised of one subordinate voting share (a “SV Share“) and one subordinate voting share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to purchase one ‎additional SV Share (a “Warrant Share“) at an exercise price of C$0.38 per Warrant Share, subject to ‎‎adjustment, at any time on or prior to 5:00 p.m. ‎‎(Eastern Time) on September 28, 2026. Each Pre-Funded Unit is comprised of one pre-funded subordinate voting share purchase warrant ‎‎(a “Pre-Funded Warrant“) and one Warrant. Each ‎Pre-Funded Warrant entitles the holder thereof to purchase one SV Share (a “Pre-Funded Warrant Share“) at ‎an exercise price of C$0.0001 per Pre-Funded Warrant Share and shall terminate upon exercise in full of ‎the Pre-Funded Warrants. ‎‎

H.C. Wainwright & Co. (“H.C. Wainwright“) acted as the exclusive placement agent for the Private Placement.

H.C. Wainwright received (i) a cash commission of $560,000.01 (equal to 8.0% of the gross proceeds of the Private Placement) and (ii) 1,964,912 compensation warrants (the “Agent Warrants“). Each Agent Warrant entitles the holder thereof to purchase one SV Share at an exercise price of C$0.38 per SV Share at any time on or prior to 5:00 pm (Eastern Time) on September 28, 2026.

The SV Shares, Pre-Funded Warrants and Warrants issued under the Private Placement were qualified by way of a prospectus supplement dated September 24, 2021 under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement“) which was filed in the Province of British Columbia. In the United States, the SV Shares, Pre-Funded Warrants and Warrants and the shares issuable upon the exercise of the Pre-Funded Warrants and Warrants were offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), and certain other jurisdictions in accordance with applicable securities laws.

The Company intends to use the net proceeds of the Private Placement for expanding clinic foot print, operating costs and acquisitions.

The Private Placement is subject to customary notices and deliveries to the Canadian Securities Exchange.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: use of the net proceeds of the Private Placement; and the receipt of all necessary regulatory and stock exchange approvals for the Private Placement.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

the potential impact of the closing of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Posted on

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Thought Leaders, Entrepreneurs, Medical Experts and Entertainment Headliners include Duncan Trussell, Shane Mauss, Alyson Charles, Dr. Carl Hart, Ifetayo Harvey, Aubrey Marcus…and a surprise special guest speaker

Vancouver, BC, September 23, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today released the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part in the two-day premier psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

The list of thought leaders who will keynote the two-day event taking place from November 6th7th, 2021, at AREA15, an immersive and experiential venue in Las Vegas, includes:

  • Duncan Trussell, stand-up comedian, podcaster and actor, host of The Duncan Trussell Family Hour
  • Jason Silva, Venezuelan-American filmmaker, philosopher, television personality, and public speaker
  • Aubrey Marcus, founder of Onnit, podcast host and best-selling author
  • Alyson Charles, former TV/radio host and athlete turned author, spiritual teacher, medium and shaman
  • Dr. Carl Hart, Ziff Professor at Columbia University, former chair of the Department of Psychology and best-selling author
  • Chris Ryan, PhD, NYT bestselling author and featured speaker at influential conferences such as TED, SXSW, and a frequent guest on The Joe Rogan Experience
  • Ifetayo Harvey, Founder and board president of the People of Color Psychedelic Collective; activist, writer and social media manager at Caring Across Generations
  • George Goldsmith, CEO and founder of COMPASS Pathways and an entrepreneur
  • Ekaterina Malievskaia, MD, Co-founder and Chief Innovation Officer for COMPASS
  • Luke Storey, Motivational speaker, podcaster, writer, meditation and metaphysics teacher, and lifestyle design expert
  • Dr. Molly Maloof, Founder of Adamo Bioscience and a lecturer within the Wellness Department of the Medical School at Stanford University
  • Ben Westhoff, Award-winning investigative reporter who writes about culture, drugs, and poverty
  • Brittany Hoogenboom, Owner and founder of Synergy Soul, a mind, body, soul, & business brand, and an intuitive business coach
  • Dr. Dave Rabin, MD, PhD, Neuroscientist, board-certified psychiatrist, health tech entrepreneur and inventor. Co-founder & Chief Innovation Officer at Apollo Neuroscience
  • Laura Dawn, Msc., Host of The Psychedelic Leadership Podcast, and a microdosing mentor for executives, who has led transformational retreats for over 10 years
  • Shane Mauss, Stand-up comedian, adventurer, podcaster, psychonaut and science enthusiast
  • Kyle Bergquist, Founder of Healing Our Heroes, co-founder of Serving Impact, author and documentary filmmaker
  • Jesse Gould, Psychedelic ranger and founder of Heroic Hearts Project
  • Zappy Zapolin, Futurist, award-winning filmmaker, and psychedelic concierge to the stars
  • Clara Burtenshaw, Partner and investor at Neo Kuma Ventures, the first psychedelics focused venture capital fund in Europe

The following business leaders, scientists and health & wellness advocates will come together for a series of thought-provoking panels on making psychedelics accessible to the masses:

Business Panelists

  • Martin Tobias, Founder of Incisive Ventures, investor and entrepreneur
  • Matt Stang, Pioneer for the cannabis industry in the U.S. and CEO of Delic Corp
  • Mark Goldfogel, Serial entrepreneur and co-founder of KERN, the first cannabis compliance company on NASDAQ
  • Sara Kennedy, Marketing entrepreneur focusing in plant-based particles
  • Joshua White, Co-founder and Executive Director of Fireside Project
  • Mitchell Gomez, Executive Director at DanceSafe
  • Sam Chapman, Executive Director at Healing Advocacy Fund
  • Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs
  • Donald Gauvreau, Founder, CEO and Chairman at Conscious Mind Labs
  • Ronan Levy, Entrepreneur, founder and Executive Chairman of Field Trip Health
  • Barbara Branaman, Co-Founder and CEO of BioReset Group, Co-Host of the Clarity Cafe Podcast, doctor of Medical Qigong, yoga and meditation teacher
  • Paul Rosen, Founder, CEO and Chairman of Tidal Royalty Corporation
  • Gary Smith, Co-founder and President of Arizona Cannabis Bar Association; author and psychedelic lawyer
  • Kraig Fox, Advisor and entertainment industry superpower ● Nanea Reeves, CEO and co-founder at TRIPP, Inc.
  • Sashko Despotovski, Investor and board member at Delic Corp
  • Dina Burkitbayeva, Founder of PsyMed Ventures, psychedelics biotech investor and entrepreneur
  • Matt Zemon, Chief Strategy Officer and co-founder at Psychable ● Jennifer Pereira, CEO of Bloom Fund and angel investor
  • Kathryn Fantauzzi, CEO and co-founder of Apollo Neuroscience
  • Hanifa Nayo Washington, Sacred activist, co-founder and cultivator of Beloved Community of Fireside Project
  • Lauren Mendelsohn, Esq., Senior associate attorney, Law Offices of Omar Figueroa
  • Sonia Weiss Pick, Co-founder and Managing Director at WPSS Investments
  • Lisa Dannen, MA, Director of Marketing & Communications, Maya Health
  • Dr. Jeff Chen, MD/MBA, Impact entrepreneur, scientist, and storyteller operating at the convergence of culture, science, and business to heal the body, mind, and planet. Cofounder & CEO of Radical Science
  • Ifetayo Harvey will also be taking part in a business panel

Wellness Panelists

  • Adam Bramlage, Founder and CEO ofFlow State, where he works one-on-one with clients to optimize their microdosing experience
  • Phoebe McPherson, Co-founder of the Hearthstone Collective, a mushroom company on a mission to help others heal with plant medicines
  • Jemie Sae Koo, CEO of Psychable.com, an online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners who can support them
  • Victor Mifsud, Creator of the personal feature-length documentary “My Neuroplastic Adventure,” taking viewers from the cutting edge of neuroscience to ancient tribal healing medicines
  • Dr. Stephanie Coleman, MD/MPH, Holistic and psychedelic medicine physician, educator, and entrepreneur
  • Dr. Devon Christie, MD, Clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management
  • Will Siu, MD, DPhil, Advisor to Bexson Biomedical and People Science has been trained by MAPS to provide MDMA-assisted therapy
  • Craig Salerno, LAC/LPC, Licensed addiction counselor and licensed professional counselor
  • Sashi Gerzon-Rose, LPC, Psychotherapist, yoga and meditation teacher, and ordained monk in the White Plum lineage of Zen Buddhism
  • David Feifel, MD/PhD, Professor Emeritus of Psychiatry at University of California San Diego and a pioneer in treating mental illness
  • Spencer Hawkswell, CEO at TheraPsilLobbyist, believes responsible drug policy requires effective organization and leadership
  • Deanne Adamson, Founder and President of Being True To You and an addiction specialist
  • Sam Ko, MD/MBA, Founder and Medical Director of Reset Ketamine
  • Lauren Taus, LCSW, Psychotherapist with a specialty in psychedelic assisted therapies
  • Amber Amendola, Psychotherapist with 10 years of health and wellness experience, focused on the healing potential of non-ordinary states of consciousness
  • Robbie Bent, Thought leader in the mental health space building a global community to improve mental health in an accessible way
  • Dr. Matt Cook, President and founder of BioReset™ Medical and Medical Advisor of Bioreset Network.
  • Dr. Harry McIlroy, MD, Family physician, licensed acupuncturist, functional medicine practitioner, osteopath, nutritionist, certified Ashtanga yoga teacher
  • Florencia Bollini, Named “The Corporate Shaman” by Forbes Magazine, one of the pioneering practitioners of the plant medicine world
  • Dr. Dave Rabin, MD, PhD, Laura Dawn, Msc., Jennifer Pereira and Dr. Jeff Chen, MD/MBA, will also be joining the wellness panels

Entertainment

Attendees will be treated to an exciting mix of live music, visual art and dancers on both evenings.

  • The greatest hits of psychedelia past, present and future will be played during The Psyche-Delic Experience, an after-party performance on Saturday, November 6, featuring DJ David Starfire and VJ Jonathan Singer, including a tribute to the Legends of psychedelia featuring the music of The Beatles, Jefferson Airplane, Jimi Hendrix, The Grateful Dead with “appearances” by Alan Watts, Timothy Leary, Terrence McKenna and Ram Das
  • A special tribute performance of Pink Floyd’s “Set The Controls For The Heart Of The Sun” created as a 360 VR immersive film
  • Futuristic psychedelia dance and techno themes featuring the music of Tipper, Sphongle, Desert Dwellers, Bedouin, and all original music by David Starfire with dancers and performance artists
  • MINDCHATTER, a project by singer, songwriter, and producer Bryce Connolly, will provide live music on Sunday, November 6. His complex sound displays influences from electronic, indie, singer-songwriter and hip-hop
  • Dance performances by Little Miss Nasty and visual art by Scott Hedstrom

The twenty hours of panels and keynotes will include an array of topics such as “Psychedelics and the Search for Truth”, “Why Are Psychedelics Medicine?”, “The Shortcomings of Wellness”, “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Psychedelics and Sobriety: The Next Frontier in Recovery“, “Microdosing,” “Psychedelic Activism,” “Digital Dosing: Technology & Innovation Powering Psychedelics”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

           ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Delic Announces C$7.0 Million Private Placement With Institutional Investor

Delic Announces C$7.0 Million Private Placement With Institutional Investor

VANCOUVER, BC September 22, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“). Pursuant to the Private Placement, the Company will issue 24,561,404 subordinate voting shares (each, a “SV Share“) (or SV Share equivalents) and warrants to purchase up to 24,561,404 SV Shares (each, a “Warrant“) at a purchase price of C$0.285 per SV Share and associated Warrant. Each Warrant entitles the holder to purchase one SV Share at an exercise price of C$0.38 for five years from the issuance date.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement.

The SV Shares and Warrants to be issued under the Private Placement will be qualified by way of a prospectus supplement under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement”) which will be filed in the Province of British Columbia. In the United States, the SV Shares, Warrants and the SV Shares issuable upon the exercise of the Warrants will be offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and certain other jurisdictions in accordance with applicable securities laws.

The net proceeds of the Private Placement will be used by the Company for expanding clinic foot print, operating costs and acquisitions.

Closing of the Private Placement is expected to occur on or about September 27, 2021, subject to satisfaction of customary closing conditions.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: Placement; and the receipt of all necessary approvals for the Private Placement the completion of the Private Placement; the amount and use of the net proceeds of the Private Placement; the anticipated closing date of the Private Placement; the qualification of the SV Shares and Warrants issued under the Private Placement and the filing of ‎the Prospectus Supplement in British Columbia; the satisfaction of the closing conditions for the Private.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Private Placement not closing as planned or at all or on terms and conditions set forth in the securities purchase agreement; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

assumptions as to the time required to complete matters related to the Private Placement; the ability to complete the Private Placement; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎Private Placement on the proposed terms; the potential impact of the announcement or consummation of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Posted on

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

​TORONTO, September 21, 2021 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Company has been included to the North American Psychedelics Index, (the “Index”), which is the underlying index of the Horizons Psychedelic Stock Index Exchange Traded Fund (the “ETF”) (NEO: PSYK).
The Index is designed to provide exposure to the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. The Index is also designed to provide diversified exposure to the psychedelics industry, at weights that can easily and cost effectively be replicated, while at the same time reflecting the evolution of the industry in a timely fashion.

The ETF invests in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.

PharmaTher is one of currently twenty-four companies to have met the requirements of listing within the ETF.  The ETF seeks to replicate the performance of the North American Psychedelics Index, net of expenses. Rebalancing of the North American Psychedelics Index occurs each calendar quarter.  At those points, all stocks eligible for inclusion are generally re-weighted by their respective float market capitalization.

Fabio Chianelli, Chief Executive Officer of PharmaTher, said, “We are pleased to be included into the first ever Psychedelic ETF as a recognition of our accomplishments in the advancement of prescription-based psychedelic pharmaceuticals.  The inclusion into the Index and ETF not only broadens our investor awareness, but also provides us with greater confidence in our business model that focuses on the research, development and commercialization of novel uses, formulations and delivery forms of ketamine for mental health (i.e. Depression), rare and near-rare neurological (i.e. Parkinson’s disease, Amyotrophic lateral sclerosis), and pain disorders.

The holdings of the Index, the ETF and its current portfolio weights are regularly updated and available at www.HorizonsETFs.com/ETF/PSYK.

The ETF is managed by Horizons ETF Management an innovative financial services company offering one of the largest suites of exchange traded funds in Canada. The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $19 billion of assets under management and 95 ETFs listed on major Canadian stock exchanges. Horizons also brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries.

About PharmaTher Holdings Ltd.

​PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics, including ketamine, to treat mental health, neurological and pain disorders.  PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing novel microneedle patches for the intradermal delivery of psychedelics.
​
Learn more at:  PharmaTher.com and follow us on Twitter and LinkedIn.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of May 31, 2021 (“MD&A”), dated September 7, 2021, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Posted on

Delic Announces Alyson Charles, Shaman and Best-Selling Author to Keynote at The World’s Premiere Psychedelic and Wellness Event: Meet Delic, November 6-7, 2021

Delic Announces Alyson Charles, Shaman and Best-Selling Author to Keynote at The World’s Premiere Psychedelic and Wellness Event: Meet Delic, November 6-7, 2021

Vancouver, BC, September 1st, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Alyson Charles will serve as one of the keynote speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, business and thought leaders.

Renowned Shaman, Best-Selling Author of ‘Animal Power,’ and Host of Ceremony Circle Podcast, Alyson Charles, went from being a national champion athlete, top-rated radio host and national daytime television talk show host, to aligning with her calling as a Shaman after a traumatic moment provided her awakening.  Since then, her ability to share ancient sacred wisdom and divine energy has allowed her to be a powerful catalyst for change that ignites  a global phenomenon. Forbes has called her both “a leading Shaman for expanding others into their full gifts and power” and “a full-fledged guide into your psyche,” Oprah Magazine named Alyson’s guided Shamanic journey “a top meditation to try,” Huffington Post championed her as “a top limit-breaking female founder,” Dazed Magazine named her “one of the top seven wellness accounts on Instagram” and Marie Claire Magazine selected her as the cover story and “the next big thing.”

“With so many people feeling a pull toward psychedelics, having education-based events with diversity and unity like Meet Delic are more important than ever,” said Alyson Charles. “I’m so excited to be able to share my deep reverence, teachings and personal experiences of my devotion and calling to Shamanism.”

Charles’ keynote appearance, Surrender & Integration: Creating Soul and Plant Spirit Alignment to Master the Journey, will discuss connecting to one’s full Divine power and spiritual gifts. Her presentation will cover how working with psychedelics is not something to be forced or taken lightly, but rather a potential process to open oneself up to with sacredness and to heed only when a genuine call to enters in. It’s a deep journey of learning to trust in oneself and Divine timing.

“Alyson brings an incredibly powerful and personal story to the journey we all must go through to connect with ourselves and how psychedelics can be powerful tools along the way,” said Delic co-founder, Jackee Stang. “I’m excited for her to share more with our diverse audience of psychonauts, business leaders, entrepreneurs and those brand new to psychedelic wellness.”

Meet Delic will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD, Joins Wesana Health Scientific Advisory Board

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD, Joins Wesana Health Scientific Advisory Board

TORONTO and CHICAGO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of distinguished psychedelics researcher and professor, Rachel Yehuda, PhD, to its Scientific Advisory Board. In this role, Dr. Yehuda will provide strategic guidance and direction to Wesana’s scientific research efforts related to psychedelic-assisted psychotherapy and traumatic brain injury (TBI).

Dr. Yehuda has been at the vanguard of trauma research and treatment for over three decades. She is a Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai, and Director of The Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai, which will further research MDMA-assisted psychotherapy and other psychedelic-assisted psychotherapies with compounds such as psilocybin to treat trauma. She is also Director of the Traumatic Stress Studies Division at Icahn Mount Sinai which includes the PTSD clinical research program.

On her appointment, Dr. Yehuda said, “The research of novel treatment approaches for trauma and other mental health conditions through psychedelics may fundamentally change our understanding of these conditions, as well as the current treatment landscape. For that to happen though, the research must be held to the highest possible standard. As part of Wesana’s Scientific Advisory Board, I look forward to offering my guidance and experience on this front as they explore ways to improve neurological health.”

“Dr. Yehuda has led federally-funded research programs that have revolutionized the current understanding and treatment of trauma and has been a driving force in the current FDA trials to study MDMA as a psychedelic therapy. Her knowledge, understanding, and guidance will be invaluable as we accelerate our efforts to research and develop treatments for TBI and other debilitating neurological ailments,” said Daniel Carcillo, co-founder and CEO of Wesana Health.

“Wesana is committed to building a team of the very best advisors, thinkers and leaders to ensure that we are operating at the highest possible level in scientific and psychedelic research and development. As a global expert in her field, Dr. Yehuda will play an important leadership role as we continue to execute on our strategic research goals,” said Chad Bronstein, co-founder and Executive Chairman.

Dr. Yehuda has authored more than 450 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. She received her PhD in Psychology and Neurochemistry and her MS in Biological Psychology from the University of Massachusetts at Amherst and completed her postdoctoral training in Biological Psychiatry in the Psychiatry Department at Yale Medical School.

Dr. Yehuda receives financial compensation as a scientific advisor for Wesana Health.

About Wesana
Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to, information concerning the anticipated timing for receipt of results from the anxiety and depression study described above and the anticipated timing for commencement and conclusion of the Pivotal Study described above. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: research and development costs remaining consistent with budgets; favorable operating conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labor stability; the ability of the Company to be successful in its research and development initiatives; and the availability of third party service providers and other inputs for the Company’s operations. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Furthermore, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, financial position, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, financial position, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: research and development of drugs targeting the central nervous system being particularly difficult; delivering data from ongoing pre-clinical and clinical studies; competition from other biotechnology and pharmaceutical companies; reliance on third parties to plan, conduct and monitor preclinical studies and clinical trials; negative results from pre-clinical and clinical trials or studies of others; unfavorable publicity or consumer perception; not achieving publicly announced milestones; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; exposure to the fluctuation of foreign exchange rates; ability to protect intellectual property; changes in patent law; requirements to share intellectual property with service providers; general economic, market and business conditions, other risks factors including those found in the Company’s Listing Statement dated May 6, 2021 filed on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.

For more information, please contact:

Media Contact:
Nick Opich / Annie Graf
KCSA Strategic Communications
Email: Wesana@kcsa.com
Phone: 212-896-1206 / 786-390-2644

On behalf of the Board of Directors:
Daniel Carcillo, Chief Executive Officer
Phone: (773) 236-7972

Primary Logo

Source: Wesana Health

Released August 31, 2021

Posted on

Delic Announces Ben Westhoff, Award-Winning Investigative Reporter Specializing in Fentanyl to Speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, August 24, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Ben Westhoff will serve as one of the headline speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, business and thought leaders.

Ben Westhoff is an award-winning investigative reporter who writes about culture, drugs, and poverty. His book Fentanyl, Inc.: How Rogue Chemists Created the Deadliest Wave of the Opioid Epidemic is the bombshell first book about the fentanyl epidemic, and he has advised officials at the top levels of government about the crisis. His previous book Original Gangstas is the definitive work on N.W.A., Tupac, and West Coast hip-hop. He came up in the alternative weeklies Riverfront Times and L.A. Weekly and has also written for The Atlantic, The Wall Street Journal, Rolling Stone, and the Guardian.

“I’ve spoken at conferences around the country, but have never been so excited as this one,” said Westhoff. “I hope to see you there!”

Westhoff ‘s keynote appearance, Fentanyl in our Drugs, will discuss how fentanyl isn’t just a problem for heroin users but how it is upending the entire recreational drug landscape. His presentation will show how fentanyl affects drug legalization prospects, dark web markets, geopolitics, and much more, and whether there’s any hope for ending the opioid crisis.

“Ben’s thought provoking journalism has exposed serious problems with the way we fight drug abuse and opens up the possibility of better treatment with far fewer side effects,” said Delic co-founder, Jackee Stang. “His objective take on the realm of treatments will be incredibly interesting and educational for the Meet Delic audience.”

Meet Delic will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Delic Announces Laura Dawn, Msc., Host of the Psychedelic Leadership Podcast, Business Consultant & Microdosing Mentor to Appear at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Vancouver, BC, August 17, 2021 – Delic Holdings Inc. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has announced that Laura Dawn, Msc. will serve as one of the headlining speakers at Meet Delic on November 6th;  catering to both curious newcomers, business and thought leaders. Her keynote, “Exploring the Intersection Between Psychedelics & Creative Problem Solving” targets business and thought-leaders, entrepreneurs, and creators.

“I am honored to be a part of Meet Delic this year, which I believe is a pivotal step in shifting society toward greater acceptance of the benefits of psychedelics for overall wellness,” said Laura Dawn, “I look forward to sharing what I have learned with business and thought-leaders, entrepreneurs, and creators on how to mindfully explore psychedelics and sacred plant medicines as powerful visionary tools for inner transformation and creative manifestation.”

Host of The Psychedelic Leadership Podcast, Laura Dawn, Msc. is a microdosing mentor for executives, and has been leading transformational retreats for over ten years. Through her signature programs and retreats, Dawn weaves together science with wisdom to teach business and thought-leaders, entrepreneurs, and creators how to mindfully explore psychedelics and sacred plant medicines as powerful visionary tools for inner transformation and creative manifestation. Through mindset and somatic coaching, she inspires people to truly expand the boundaries of what they believe is possible and embark on the path of heart-centered leadership to influence meaningful change.

Laura Dawn has a degree in Finance and Entrepreneurship and over two decades of exploring altered states of consciousness. Currently, she is completing a Masters in Science specializing in Creativity Studies & Change Leadership, exploring the intersection between psychedelics and creative problem-solving to help corporate teams unlock innovative solutions to the complex challenges we face.

“Laura Dawn is well-known among the business leaders and entrepreneurial circuits for helping share the benefits of psychedelics in personal and professional development and is exactly the voice we look to highlight at Meet Delic,” said Meet Delic Co-Found and Executive Producer,  Jackee Stang. “Her coaching, life experience and expertise will help today and tomorrow’s leaders in their own careers and lives.”

In addition to her solo appearance, Dawn will lead a panel titled, ‘Microdosing’ alongside Psychable.com ’s CEO: Jemie Sae Koo, Flow State Worldwide’s CEO: Adam Bramlage, and Phoebe McPherson, the Co-Founder of Hearthstone Collective.

The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

The twenty hours of panels and keynotes will include anarray of topics such as: “Psychedelics and Sobriety: The Next Frontier in Recovery.” “Why Are Psychedelics Medicine?” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “PTSD Reset and Recovery,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love,”“Psychedelic Activism”, “Drug Use for Grown-Ups,” and much more! Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, www.meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com